Combination Treatment with an Antibody–Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian Cancer

BACKGROUND: Recurrence occurs in over 75% of women with epithelial ovarian cancer despite optimal treatment. Selectively killing tumour cells thought to initiate relapse using an antibody–drug conjugate could prolong progression-free survival and offer an improved side-effect profile. A1mcMMAF is an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Y. Louise, Sapra, Puja, Bolton, James, Chua, Jia Xin, Durrant, Lindy G., Stern, Peter L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684567/
https://www.ncbi.nlm.nih.gov/pubmed/31332693
http://dx.doi.org/10.1007/s11523-019-00650-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684567/
https://www.ncbi.nlm.nih.gov/pubmed/31332693
http://dx.doi.org/10.1007/s11523-019-00650-8

Ejemplares similares